

# **Patient Satisfaction and Medication Noncompliance following Percutaneous Coronary Intervention in Armenia**

(A cross-sectional study)

Master of Public Health Integrating Experience Project

Professional Publication Framework

by

Seda Aghabekyan, MD, MPH Candidate

Advisor: Michael Thompson MS, DrPH

Reader: Lusine Abrahamyan MD, PhD (c)

College of Health Sciences  
American University of Armenia  
Yerevan, Armenia, 2009

## Table of Contents

ABBREVIATION LIST .....	II
ACKNOWLEDGEMENTS .....	III
ABSTRACT .....	IV
1. INTRODUCTION.....	1
1.1 BACKGROUND/ LITERATURE REVIEW .....	1
1.2 PATIENT SATISFACTION .....	7
1.3 NORK-MARASH MEDICAL CENTER (NMMC) AND THE STANDARD OF CARE .....	8
1.4 AIM OF THE STUDY/ RESEARCH QUESTIONS/ OBJECTIVES.....	9
2. METHODOLOGY .....	11
2.1 STUDY DESIGN .....	11
2.2 STUDY POPULATION .....	12
2.3 SAMPLING METHODOLOGY.....	13
2.4 SAMPLE SIZE .....	14
2.5 STUDY INSTRUMENT.....	14
3. ETHICAL CONSIDERATIONS.....	15
4. DATA ANALYSIS.....	16
5. RESULTS .....	18
5.1 DESCRIPTIVE STATISTICS .....	18
5.2 MEDICATION NONCOMPLIANCE .....	19
5.3 PATIENT SATISFACTION .....	19
5.4 STANDARD 2-TAILED T-TESTS AND $\chi^2$ TESTS .....	20
5.5 BIVARIATE LOGISTIC REGRESSION.....	20
5.6 MULTIPLE LOGISTIC REGRESSIONS.....	21
6. DISCUSSION .....	22
7. STUDY LIMITATIONS .....	25
8. CONCLUSION AND RECOMMENDATIONS.....	26
REFERENCE LIST.....	28
TABLES.....	37
FIGURES.....	51
APPENDIX 1. JOURNAL FORM .....	52
APPENDIX 2. QUESTIONNAIRE (ENGLISH & ARMENIAN) .....	53
APPENDIX 3. CONSENT FORM (ENGLISH & ARMENIAN).....	65

## **Abbreviation List**

- CHD** - Coronary Heart Disease
- WHO** - World Health Organization
- CABG** - Coronary Artery Bypass Grafting
- PCI** - Percutaneous Coronary Intervention
- AHA** - American Heart Association
- DES** - Drug-Eluting Stent
- Tx** - Thromboxane
- ADP** - Adenozine DiPhosphate
- AGATE** - AGgrenox versus Aspirin Treatment Evaluation
- NMMC** - Nork-Marash Medical Center
- MAS** - Morisky Adherence Scale
- PSQ** - Patient Satisfaction Questionnaire
- ROC** - Receiver Operating Characteristics
- AUA** - American University of Armenia
- MI** - Myocardial Infarction

## **Acknowledgements**

I would like to express my deepest gratitude to my adviser Michael Thompson and my reader Lusine Abrahamyan. With their valuable advices and comments I was able to implement my MPH Integrating Experience Project.

I am also grateful to Dr. Varduhi Petrosyan for her encouragement and support in the most difficult periods of studying at AUA.

I appreciate Liana Hakobyan for her valuable advices and assistance, and the staff of Nork-Marash Medical Center for their kind treatment and help.

Finally, I would like to appreciate my course mates for their support and my family members for their patience.

## Abstract

**Background:** Coronary heart disease (CHD) is a major cause of morbidity and mortality throughout the world. One of the expected treatments for CHD is percutaneous coronary intervention (PCI), particularly drug-eluting stent (DES) placement. Dual antiplatelet therapy consisting of aspirin and a thienopyridine drug should be given for at least a full year for patients without major risk for bleeding. Inability of the patient to comply with the recommended therapy for DES can impact reaching therapeutic goals, often leading to a deterioration of health status. Increased risk of stent thrombosis, higher incidence of death, reinfarction, or rehospitalization are associated with medication noncompliance. Low patient satisfaction from the care received and poor health status complex the problem forming a vicious cycle with medication noncompliance.

**Objective:** The project evaluated the relationship between noncompliance with antiplatelet therapy (Aspirin, Clopidogrel (Plavix)), patient satisfaction, health status and medication affordability/cost in Nork-Marash Medical Center (NMMC) following DES placement.

**Methods:** The analytical cross-sectional telephone survey drew on a study population that consisted of a simple random sample of 375 patients aged 18 and over, who had undergone DES placement surgery at NMMC from 2006 to 2008. Among the survey items were the Morisky Adherence Scale Score (MAS), used to measure compliance (adherence) to medications, and the Short-Form Patient Satisfaction Questionnaire (PSQ-18), used to measure satisfaction with interpersonal manner, communication and general satisfaction.

**Results:** Mean age of the participants was  $59 \pm 10$  years ( $n=271$ ). Most (88%) were male. The proportion of noncompliant patients was 31.0% ( $n=84$ ). Only 8.1% (22 patients) reported “fair” or “poor” health status. Among the participants, 77.5% were generally satisfied with their care, 95.9% were satisfied with their caregivers’ interpersonal manner, and 88.2% were satisfied with communication with their caregivers. Virtually all (97.8%) were satisfied with discharge instructions. In bivariate logistic regression analyses, age, gender, health status, smoking status and cost were associated with medication compliance ( $p < 0.05$ ). Compliance was not associated with satisfaction. Multiple regression analysis revealed an association between medication compliance and cost (OR=2.57, 95% CI=1.33-4.97), “very good”/ “excellent” health status (OR=2.17, 95% CI=1.18-4.01), and age (OR=1.06, 95% CI=1.03-1.09).

**Conclusion:** Consistent with the literature, health status, and age emerged as independent predictors of medication compliance. Patients often cited out-of-pocket costs as a contributing factor to noncompliance. Clinicians need to recognize and appropriately address these factors in following-up their patients. Further research is needed to account for time since stent placement and determining the impact of medication noncompliance on health outcomes. In addition to following the treatment guidelines, physicians should continually reinforce lifestyle advice for secondary prevention of heart attacks (e.g., smoking cessation, controlling high blood pressure).

# **1. Introduction**

## **1.1 Background/ Literature Review**

Coronary heart disease (CHD) is a major cause of morbidity and mortality throughout the world. According to WHO, CHD is a disease of the blood vessels supplying the heart muscle (1). CHD was the leading cause of mortality worldwide with 7.2 million deaths, accounting for 11.2% of all deaths in 2004 (2). Both surgical revascularization (coronary artery bypass grafting (CABG)) and percutaneous coronary intervention (PCI) are expected treatments for this condition (3). The acute success rate of percutaneous coronary intervention (PCI) has increased ever since its introduction, despite a widening scope of indications (4; 5; 6). Currently stents are placed in more than 50% of elective interventions, partly because they are highly effective in avoiding vessel closure (7; 8). Stenting, however, is associated with significant risk of complications, such as (sub)acute thrombosis, which occurs in 1–4% of the procedures (9; 10). Thrombosis plays a major role in acute vessel closure both after balloon angioplasty and after stenting (11).

According to the science advisory from the American Heart Association (AHA), American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and the American Dental Association with representation of the American College of Physicians, dual antiplatelet therapy consisting of aspirin and a thienopyridine drug such as clopidogrel (Plavix) or ticlopidine (Ticlid) should be given for at least a full year and perhaps even longer following certain types of stent placements for patients without major risk for bleeding (12).

The leading adverse event associated with early discontinuation of dual antiplatelet therapy is stent thrombosis, leading to an acute myocardial infarction with a 25 to 40% mortality rate. Premature discontinuation of the dual therapy is the single greatest predictor of stent thrombosis (12). Patients at even higher risk for stent thrombosis such as those with acute coronary syndromes, long stents, overlapping stents, diabetes, low ejection fraction, advanced age, and renal failure may need antiplatelet therapy for even longer, perhaps indefinitely (12). Two basic types of stents are available: bare metal and drug-eluting. Bare metal stents tend to allow growth of endothelial tissue to line the metal lumen in about 1 to 3 months. Until that occurs, the probability that the stent will thrombose is high. Once the bare metal is covered, the potential for stent thrombosis decreases and thus, antiplatelet therapy was thought to be less important after the healing period. A problem with bare metal stents is that the tissue may continue overgrow and eventually occlude the stent. To overcome that problem, drugs are imbedded in second generation stents to slow the growth of the endothelial lining, but the drugs also slow the rate of healing. These second generation drug-eluting stents (DES) therefore require longer periods of dual antiplatelet therapy, up to a year or more. They are more likely to be involved in stent thrombosis if antiplatelet therapy is interrupted during the first year (12).

According to Food and Drug Administration surveys, in 1996 only 26% of patients said that their physicians told them about their medication's side effects and how and when to take it (13). In 2004, the figure was unchanged. A similar measure of pharmacist communication actually dropped from 14% in 1996 to 6% in 2004 (13).

Medication noncompliance can be harmful for the patient and impact reaching therapeutic goals, often leading to a deterioration of health status. Patients commonly fail to take their medications

as directed, leading to unnecessary hospital admissions and even death, costing the health care system as much as \$177 billion a year (13).

Approximately 50% of 1.8 billion prescription medications dispensed annually in the United States are not taken correctly by patients (14; 15). These errors lead to increased health care costs (16), morbidity and mortality (17).

In a study of 652 patients with a DES (drug-eluting stents), premature discontinuation of clopidogrel was associated with a 30-fold increased risk of stent thrombosis. Greater than 25% of patients who stopped clopidogrel in the first month suffered from stent thrombosis (12).

Similarly, of patients who had DES placed after having an acute myocardial infarction and were discharged on thienopyridine therapy, 68 (13.6%) stopped therapy within 30 days. From patients who stopped thienopyridine therapy 7.5% died in the first 11 months if they stopped therapy compared with 0.7% who did not stop (12).

A recent study of patients recovering from ischemic stroke showed that more than 10% were noncompliant with aspirin (18). Noncompliance, detected by serum TX assay and on interview, occurred in 16% of the population and was associated with 4-fold higher incidence of death, reinfarction, or rehospitalization at 12 months of follow-up (19). Consistent with these findings, poorly compliant patients in the Physicians Health Study derived less benefit than compliant patients (17% versus 51% reduction in myocardial infarction compared to placebo) (20).

Noncompliance with therapy must be also assumed, when failure to respond to aspirin is assessed. Inadequate primary pharmacological effects may lead to the failure to respond to aspirin or “aspirin resistance”. Depending on the population studied, the assay used, and also the

definition applied, prevalence of aspirin resistance is estimated to be between 5% and 65% (21). Studies show, that “Clopidogrel resistance” is more common than “aspirin resistance” (22). Although the results vary owing to differences in methods used and definitions of “resistance”, studies using ADP-induced platelet aggregation and a cut-off point at less than or equal to 10% inhibition (which is an extremely modest treatment goal) have found 5–44% “Clopidogrel resistant” patients (23). The dosage and time since dosing are important determinants; increasing the clopidogrel maintenance dose in “low responders” has been advocated despite lack of clinical documentation (23; 24).

Studies suggest that the prevalence of noncompliance may even be higher. In one study about treatment for dyslipidaemia, persistence with statins in a secondary prevention cohort (patients with a diagnosis of myocardial infarction or angina, CABG or angioplasty, or had used nitrates within the year before the date of the first prescription) had fallen to 71% after 6 months of treatment and declined to 45% after 3 years. Comparable results were obtained in the primary prevention cohort (patients without a diagnosis of cardiovascular disease or drug markers in the year prior the date of the first prescription) where the figures were correspondingly 65% and 35% (25).

Likewise, a study about medication noncompliance in chronic kidney disease revealed, that the prevalence of medication noncompliance was 36.9% ([95% CI], 28.6%-45.8%) (26).

Finally, a study assessing noncompliance in atherothrombotic clinical trials (27), the AGgrenox versus Aspirin Treatment Evaluation (AGATE) trial reported at AHA (28), revealed that almost 10% among screened post-ischemic stroke patients, consciously discontinued taking their prescribed aspirin. The study suggests that firstly, if aspirin noncompliance was so high in the

AGATE trial, most probably there are even greater risks for noncompliance in patients treated with ticlopidine and clopidogrel, due to the increased frequency of minor bleeding complications (29). Moreover, the incidence of noncompliance will be higher in case if the most effective antiplatelet agents are used, diminishing the power for the superiority of the primary vascular outcome (29).

For further complicating risk assessment the high level of noncompliance may lead to significantly underestimating the risk of bleeding events (29). Therefore, noncompliance should be recognized as a confounding factor in negative outcomes and treatment failures in clinical trials. Certain patients are discontinuing their antiplatelet medications without informing their physicians, which results in a critical rebound of platelet activation and higher vascular mortality (27). Therefore, an increased understanding of the reasons for noncompliance and lack of persistence with prescribed medication is an important step toward improving treatment effectiveness, and patient health.

Studies show, that many factors are associated with noncompliance. Such demographic variables as age (25; 30), gender (31), nationality (32), marital status (33), education (34), poor knowledge regarding prescribed medicines (26; 33), income (35), employment (34) are related to medication noncompliance.

Patient characteristics generally influencing their health such as smoking status (30), lack of low fat diet and exercise (30), poor memory (36), preexisting cardiovascular disease (33), co-morbidities; diabetes (25), hypertension (25), are also associated with noncompliance.

Factors such as lack of discharge instructions about medications or a cardiac rehabilitation referral (33), occurrence of adverse reactions (30), absence of concomitant medication (30), number of medications taken (37) and cost of medications (33) affect patients' decision to take medications as prescribed. In addition, for people living in rural areas inconveniences and challenges with travelling greater distances to pharmacies may negatively influence medication compliance (38).

From the perspective of patient satisfaction, the factors associated with noncompliance with prescribed medications are low patients satisfaction with the physician (30) and with the health care service provided (26). Satisfaction with the relationship between health care providers and patients (factors like lack of confidence in physician's ability to help the patient (38), lack of satisfaction with the concern shown by the physician (38) and lack of satisfaction with the relationships with office staff (38)) is also associated with medication noncompliance. Poor opinions of the quality of services are also related to noncompliance (26).

Lack of effective communication between the patient and health care provider often leads to decreased reliance on health care and treatment, resulting in poor disease control and noncompliance (39). Dissatisfaction with the discharge instructions is an independent correlate of noncompliance (40).

In several studies, medication noncompliance is associated with fair or poor health status (41; 42). These findings suggest that fair or poor health status of patients affects their decision to follow a prescription regimen. In addition, since there is a lack of positive results in health conditions of these patients due to poor health status, the patients just stop taking the medications or do not follow instructions because they perceive no benefit in regular treatment (31). Besides,

patient's health status and the severity of illness are also important predictors of the patient's overall satisfaction level (43; 44; 45; 46). In this situation factors like being unsatisfied with care received or with relationships with the physicians and personnel of the hospital may complex the problem, forming a vicious cycle with poor health status and medication noncompliance.

## **1.2 Patient Satisfaction**

Medical care aims not only to improve health status but also to respond to patient needs and to ensure patients' satisfaction with care (47); thus, hospitals look for a reliable way of following-up their patients, by evaluating the patient's quality of life, and at the same time improving the standard of treatment by scoring and reflecting the patient satisfaction. As a result, patient satisfaction has become the most important direct feedback to providers on the quality of services and the relationship of services to treatment outcomes for many health care organizations (48). The assessment of satisfaction with care among hospitalized patients is increasingly recognized as a major component of quality management (49).

Various dimensions of patient satisfaction have been identified by patient satisfaction surveys aiming to improve healthcare delivery. According to the studies, quality of medical information and relationship with staff that are related to interpersonal aspects of care, and are both predictors of patient opinion on care (50). The relationship between health care providers and patients (i.e. interpersonal skills) has been reported to be the most influential factor for patient satisfaction (51; 52). As it was mentioned patient's overall satisfaction is also affected by patient's health status and the severity of illness. Besides, patient characteristics such as age and education may influence a patient's assessment of hospital performance as well (43; 51; 53). Studies have

shown that satisfaction also depends on technical quality, communication, financial aspects of care, time spent with doctor, and accessibility of care (54).

The assessment of satisfaction with care among hospitalized patients is recognized as a major component of quality management. Continuous quality improvement, comparison of hospital performances, and demands for accountability are some of the reasons that lead hospitals to measure patient satisfaction.

Different dimensions of patient satisfaction are associated with medication noncompliance in various studies. Factors like severity of illness and poor health status are related to both, medication noncompliance and patient satisfaction. Thus, looking for associations between medication noncompliance and aspects of patient satisfaction, these factors will be treated as potential confounders.

### **1.3 Nork-Marash Medical Center (NMMC) and the standard of care**

Nork-Marash Medical Center (NMMC) provides a wide range of cardiovascular health care services to adults and children in Armenia including inpatient and outpatient treatment and follow-up of patients with congenital heart disease, coronary artery disease, and congestive heart failure. The hospital is specialized in all types of interventional cardiac procedures, such as balloon angioplasty, coronary artery revascularization with stent placement or coronary artery bypass grafting, surgical valve replacements using biological and mechanical prosthetic valves.

NMMC was established in 1993. The center has an Outpatient Clinic with three Departments (Adult Cardiology, Pediatric Cardiology and Arrhythmology), an Inpatient Clinic Surgical Department, and an Intensive Care Unit.

Approximately 400 patients undergo CABG and 300 patients undergo stent placement each year at NMMC. These patients come to NMMC from different parts of Yerevan, and from other cities and villages of the republic.

As a standard of care for PCI patients with DES, Nork-Marash Medical Center follows the guidelines for Percutaneous Coronary Intervention from AHA, prescribing clopidogrel and aspirin after DES placement (12).

The center organizes many quality assurance and improvement activities and projects, such as a multi-faceted Quality Assurance project that was launched at NMMC by AUA/CHSR in 2000 and lasted 5 years. Center's internal quality improvement is based on Continuing Quality Improvement model (55).

For internal quality evaluation purposes a survey was conducted in NMMC to assess the noncompliance with antiplatelet therapy in patients with stent placement and their satisfaction with care and with physician-patient relationship and to find an association between noncompliance and patient satisfaction. The survey aimed to yield reliable and valid measures of concepts that have both theoretical and practical significance to the planning, administration, and evaluation of health services delivery programs (56).

#### **1.4 Aim of the Study/ Research Questions/ Objectives**

The project evaluated the relationship between noncompliance with antiplatelet therapy (Aspirin, Clopidogrel (Plavix)), patient satisfaction, health status and medication affordability/cost in NMMC following stent placement.

The following research questions have been addressed:

1. What is the prevalence of medication noncompliance following stent placement in NMMC?
  - a. What characterizes patients who are compliant with prescribed medications compared to noncompliant patients?
  - b. What characterizes patient satisfaction with care, discharge instructions and with physician-patient relationship (communication, interpersonal manner) in NMMC, in patients with stent placement?
2. Does an association exist between noncompliance and patient satisfaction, health status and medication affordability/cost?

The specific objectives of the study were:

1. Estimate the prevalence of noncompliance with medications in patients with stent placement in NMMC.
2. Compare the characteristics of patients who are compliant with prescribed medications compared to the patients who are not compliant.
3. Measure patient satisfaction with care, discharge instructions and with physician-patient relationship in NMMC in patients with stent placement.
4. Evaluate the association between noncompliance and patient satisfaction, health status and medication affordability/cost.
5. Explore the main obstacles to compliance and make further recommendations to improve the situation with noncompliance with the prescribed medications in patients with stent placement and their health outcomes.

## **2. Methodology**

### **2.1 Study Design**

The study design is analytical cross-sectional as the aim of the study is to estimate prevalence of noncompliance and all measurements on a study subject are performed at a single point in time (57). As long as the study is not only descriptive but also aims to find an association between different variables (compliance, patient satisfaction and demographic data), it is more analytical (57).

The chosen design has the following advantages: firstly it is useful in identifying associations between variables of interest, it is cheap and simple, and data collection is performed quickly by only “one-time” interview. In addition attrition is not an issue in this case and it is ethically safe. (58). However, the study design has some disadvantages like it does not permit for distinction between cause and effect relationships in the associations, does not economize on subjects and is not useful for rare cases. The design may also be susceptible for recall bias and confounders may be unequally distributed. Finally the observed differences may be due to age/time effects or cohort effects (58).

The study was conducted by telephone interview technique. The selection of this technique is explained by the following several reasons. Patient visits to health facilities are infrequent making face-to-face interviews in the facility difficult. Moreover, telephone interviewing is safe in comparison with personal interviews at home, since there is no need for researcher to travel long distances or to enter unfamiliar houses.

However, telephone interview technique has several limitations. Firstly, some people will not be eligible because of not having phone numbers and also they can be absent from their residence. In addition, the refusal rate will likely be higher than for face-to-face interviews (57). Still, the telephone interview is the most appropriate for this study's aims and the dispersion of the target population.

## **2.2 Study population**

The target population for this study consisted of patients who underwent drug-eluting stent (DES) placement surgery in NMMC from 2006 to 2008 year and were still alive at the time of survey. Information about the patients was extracted from NMMC cardiovascular information registry, where all the information about the patient including date of stent placement, the name of the vessel(s), the type of the stent implanted, and demographic data is provided. The telephone numbers of the patients were also extracted from these records. The inclusion and exclusion criteria were applied for those who were willing to participate.

Inclusion criteria were the following:

- Aged more than 18 years
- Residing in Armenia at the time of the survey
- Able to give consent to telephone interview.

Exclusion criteria were the following:

- Patients with CABG in the past
- Patients with stent replacement (stent placement more than one time before the call was made)

The exclusion of the patients with stent replacement is explained by the fact that additional problems with health may result in decreased reliance of treatment and negatively affect medication compliance. Besides, answers of these patients may be incorrect because of confusing prescriptions and their duration of intake after stent placement and after replacement.

As at least one year has elapsed since the patients were treated, those patients who died during this time period (“drop outs”) might be different (e.g., more severe, more likely to have been noncompliant, less satisfied with their care) from those remaining in the study. Efforts were made to assess patient’s health status from discharge and follow-up notes, to partly address this issue by controlling, in a limited fashion, for severity of illness.

### **2.3 Sampling methodology**

NMMC provided a complete roster of these patients to establish the sampling frame. After checking for appropriate completeness of the list those who did not meet inclusion criteria or had any incomplete information were dropped out. Duplicates were dropped out.

The study population was chosen by simple random sampling which is known to be relatively unbiased. Simple random sampling is known to be the best way to give opportunity to each patient to be chosen. This recommended sampling strategy is the best alternative as there is a complete sampling frame available. Besides, the eligibility of the patients was not affected by not having telephone numbers, as long as all the patients had provided telephone numbers to contact.

The required information on patients for study population was collected in a Journal form (Appendix 1), that included the name of the patient, telephone, place of living, date of undertaken stent placement, date of contact and result of contact by telephone (response status).

## 2.4 Sample size

According to the published literature, noncompliance rates for the general population typically range from 10% to 40%. Thus, to have 80% power to detect 20% true difference in proportion of noncompliant patients between the two satisfaction groups (satisfied and unsatisfied), the following assumptions were made in estimating the required sample size:

- The prevalence of noncompliance in satisfied group was assumed 20%
  - The prevalence of noncompliance in unsatisfied group was assumed 40%
  - The ratio of number of people satisfied to number of people unsatisfied was assumed 4:1
- (65)
- Type I error rate ( $\alpha$ ) = 0.05; power ( $1-\beta$ ) = 0.80

The *statcalc* utility in EpiInfo was used (66) to calculate the required sample size of 270

Anticipating an 80% response rate (67) and a 90% eligibility rate, the sample needed to achieve a final sample of 270 was estimated as 375 ( $n=270/(0.8*0.9)$ ).

## 2.5 Study instrument

The study instrument was formed from questions from validated questionnaires adapted for the study purposes and to the NMMC context. Particularly the survey questions elicited information about patients' demographic characteristics, medication compliance, and patient satisfaction (the key variables of interest are provided in Table 1). Questions about demographic information were adopted from Household Health Survey conducted by CHSR at AUA (59) and also from the National Survey of People with Diabetes (60). Questions regarding health status of the patients were taken from SF-36 (61) and questions regarding compliance were taken from the

Morisky Adherence Scale (MAS) to assess adherence to medications (62). MAS is a 4-item self-report scale with original binary response option (yes/no). The classification of the patients as compliant (adherent), or as noncompliant (non-adherent) depended on the proportion of binary answers (63).

For assessing patient satisfaction a validated patient satisfaction questionnaire (PSQ-18) (64) was used. The questionnaire yields separate scores for each of seven different subscales. In the questionnaire each item is accompanied by five response categories (strongly agree, agree, uncertain, disagree, strongly disagree). As long as some items are worded so that agreement reflects satisfaction with medical care, while other items are worded so that agreement reflects dissatisfaction with medical care, all the items were scored so that high scores reflect satisfaction with medical care. From the seven subscales three (General Satisfaction, Interpersonal Manner and Communication) were adapted for NMMC to evaluate the health care received by patients who underwent stent placement surgery in NMMC.

### **3. Ethical Considerations**

The research proposal was reviewed and approved by the Institutional Review Board (IRB) within the College of Health Sciences at the AUA.

Oral consent was provided to patients in this minimal risk study evaluating the internal quality of services at NMMC. The survey did not include private or sensitive items, confidentiality was assured. Although the collected data included the information on patients' names and telephone numbers, these data were not entered into the computerized database; instead, a coded number

was used. After data entry and cleaning, the paper forms, containing respondent identifiers were destroyed. At that point anonymity was assured.

#### **4. Data Analysis**

After the interviews were completed, all available data were entered into the SPSS 11.0 for windows statistical package. Data cleaning included range checking and logical inconsistencies in responses, skip patterns, and missing data. Double entry of data from 20 randomly chosen questionnaires was performed. Data were analyzed through the Stata 10 statistical software.

Frequency analysis and descriptive analysis (Mean  $\pm$  SD for continuous variables and frequencies for categorical variables) were conducted for the variables of interest and relevant socio-demographic variables (Table 1).

Prevalence of noncompliance was assessed with 95% confidence intervals (CI). Patients, who were compliant with three or more of the four MAS items (MAS score 0 or 1) were classified as compliant (adherent). Patients compliant with fewer than three of the four items (MAS score 2, 3 or 4) were classified as noncompliant (non-adherent) (63).

Mean satisfaction scores (Mean  $\pm$  SD) was calculated for each of the three scales by averaging the scores of items within each scale. Each item was accompanied by five Likert-type response categories (strongly agree, agree, uncertain, disagree, strongly disagree), scored from 1 to 5 with higher scores reflecting increased satisfaction with medical care. Scores 4 and above, corresponding to “agree” and “strongly agree” were selected as the point at which to dichotomize the variable into satisfied versus unsatisfied.

A variable “smoking status” was obtained by combining two questions regarding smoking (“never”, “former”, “current”). The two questions were the following: “Have you ever smoked cigarettes?” and “Do you currently smoke cigarettes?”. Another variable “current smoking level” regarding smoking measured the number of cigarettes smoked per day.

Health status was a subjective measure self-reported by the patient, and measured by the categories: “excellent”, “very good”, “good”, “fair” and “poor”. A new variable reduced these responses to three categories by using the middle value “good” as a referent, and combining the two responses above and the two below into a single category each.

Differences in characteristics between compliant and noncompliant patients were compared using either a standard 2-tailed t-test (for continuous variables) or a  $\chi^2$  test (for dichotomous variables).

Crude odds ratios were used to assess the relationship between each of the independent variables and the dependent variable (medication compliance).

Because of potential interaction between health status and patient satisfaction (as the healthier is the patient, the higher is the satisfaction from health care) a new variable was tested. Interaction between gender and smoking level was also taken into consideration.

Independent predictors of compliance (including patient satisfaction) were assessed using multiple logistic regression analysis. Backward stepwise technique was used for model building including all significant variables at  $p > 0.05$  in univariable analysis. The final model was checked for potential confounders and effect modifiers. The model fit was assessed using the Hosmer-Lemeshow goodness-of-fit statistic and area under the Receiver Operating Curve.

## 5. Results

### 5.1 Descriptive statistics

To achieve the target of 270 respondents, a total of 375 patients were selected for interview. Ultimately 271 patients completed interviews during the data collection period (from 17 March to 08 May). Of the 104 nonrespondents, 1 (0.26%) refused to participate, 1 stopped the interview (incomplete), 7 patients were dead, 10 patients were absent from the country, and 85 patients were unavailable (wrong number, no answer, moved, etc.). The response rate was 72.3%.

Demographic and other characteristics of study participants are listed in Table 2. Their mean age was  $57.51 \pm 9.81$  years and 87.82% were male. Of the participants 98.89% were Armenian, 96.31% were married, 5.90% had an incomplete education (completed less than 10 years), 22.14% had completed schooling (10 years), 18.45% had completed professional technical education (10-13 years), 49.82% had graduated from an institute/university, and 3.69% were postgraduates. Almost 53% were currently employed; the majority of unemployed (47.23%) were retired (56.15%). These patient demographics are consistent with prior studies on CAGB patients (67) and post acute myocardial infarction (MI) patients (68).

Among the participants, 91.88% evaluated their health in general as “excellent”, “very good” or “good”, with only 8.12% reporting “fair” or “poor” health status. Nearly half (46.86%) were former smokers, 30.63% currently smoked, and 22.51% had never smoked. Among current smokers, the mean number of cigarettes smoked per day was  $4.94 \pm 9.38$ . Among chronic conditions, 19.19% reported having diabetes diagnosed by a doctor, and 49.82% having high blood pressure. About 24.35% have had a heart attack. Virtually all (98.89%) reported that they

had received clear and understandable discharge instructions; 0.37% did not receive and 0.74% did not remember. Over three-fourths (78.23%) reported always receiving a cardiac rehabilitation referral; 18.08% reported receiving a referral some of the time, and 3.69% rarely or not at all.

## **5.2 Medication noncompliance**

Scores for the Morisky Adherence Scale range from 0 to 4. As described above, respondents were categorized as compliant or noncompliant, using the cut-off point between cores 1 and 2. The proportion of compliant patients was 69.00%, and the proportion of noncompliant patients 31.00% (Table 3). The results of responses to individual MAS items are presented in Table 4. Of the 271 respondents 62 (22.87%) cited one or more reason for noncompliance, while the remaining 209 (77.13%) did not cite any reason. The most commonly cited reasons for medication noncompliance were: 19.19% (52 patients) were unable to buy medications because of the cost, 3.69% (n=10) complained of absence of prescribed medication in the available drug-stores), 1.48% (n=4) patients reported travelling distance to procure the medicine as a problem, 1.11% (n=3) had forgotten to take medications because of poor memory, 0.74 % (n=2) perceived that medicines did not help. Interestingly, no one mentioned side effects as a reason for medication noncompliance.

## **5.3 Patient Satisfaction**

As expected, scores for three individual aspects of satisfaction showed that the population was skewed toward high satisfaction (Figure 1). This finding confirmed the primary assumption underlying the cut-off point between 3.5 and 4.0 for dichotomizing satisfaction. Dichotomization

(Table 5) resulted in 77.5% (95% CI 72.5 - 82.5) being “generally satisfied”, 95.9% (95% CI 93.6 – 98.3) being satisfied with “interpersonal manner”, and 88.2% (95% CI 84.3 – 92.1) were satisfied with “communication”. Virtually all (97.8%, 95% CI 96.0 – 99.5) were satisfied with discharge instructions.

#### **5.4 Standard 2-tailed t-tests and $\chi^2$ tests**

Compliant patients were significantly more likely to be older, mean 58.94 years versus 54.32 years,  $p = 0.000$  (Table 6). Women were more likely than men to be compliant with medication regimens: 15.51 % versus 4.76%,  $p = 0.012$ . Compliant patients were more likely to be “never smokers” (26.74% versus 13.09%,  $p = 0.045$ ) and currently smoke fewer cigarettes (4.29 versus 6.40,  $p = 0.043$ ). Compliant and noncompliant patients significantly differed in health status: compliant patients were more likely to have “good” (42.78% versus 26.19%) health status. Patients not having difficulties with cost of medications were more likely to be compliant: 85.03% versus 71.43%,  $p = 0.009$ . Surprisingly, compliance was not associated with satisfaction, neither by the aggregate measure of satisfaction or for any of its constituent domains (Table 6).

#### **5.5 Bivariate logistic regression**

Table 7 summarizes the bivariate logistic regression analyses (crude odds ratios). Factors, such as age, gender, health status, smoking status and cost were associated with medication compliance. No association was found between compliance and any aspects of patient satisfaction (Table 7). Older patients are more compliant. The odds of being compliant with prescribed medications increases by 5% with each year of patient age (OR=1.05, 95%CI 1.02 – 1.08,  $p=0.000$ ). Women are 3.67 times (95%CI 1.25 – 10.80,  $p=0.018$ ) more likely to be

compliant than men. Patients with “very good” /“excellent” health status were 2.05 times (95%CI 1.15 – 3.66, p=0.015) more likely to be compliant compared to patients with “good” health status. The odds of being compliant are 2.27 times greater (95% CI 1.22 – 4.22, p=0.010) among the patients for whom the cost for buying medications is not a problem. Current smokers were by 60% less likely (OR=0.40, 95%CI 0.18– 0.90, p=0.028) to be compliant compared to never smokers, and former smokers were by 59% less likely (OR=0.41, 95%CI 0.20 – 0.88, p= 0.021) to be noncompliant, compared to never smokers.

## **5.6 Multiple logistic regressions**

Multiple logistic regression was then used to build model, that best fits the empirical data (Table 8). Potential interactions between health status and patient satisfaction (as the healthier is the patient, the higher is the satisfaction from health care) were tested. No significant interaction was found. Interaction between gender and smoking level was statistically significant (OR=1.35, 95% CI 1.03-1.78, p=0.031). All covariates identified as statistically significant (p<0.05) in the bivariate analysis (age, gender, health status, smoking status and cost) were included in a multiple logistic regression analysis. Gender and smoking status were no longer significant in the model. The final model was defined by using backward stepwise technique. The interaction term between gender and smoking level was not used in the final model, based on the results of collinearity analyses. The final model is presented in Table 8.

Multiple regression analysis revealed that cost, health status and age were the independent predictors of medication compliance. After adjusting for health status and age, the odds of being compliant was 2.57 times greater (95% CI 1.33 – 4.97) among the patients for whom the cost for buying medications is not a problem. Similarly, the odds of being compliant with prescribed

medications increased by 6% for each year of age (OR=1.06, 95%CI 1.03 – 1.09), and by 2.17 times (95% CI 1.18-4.01) for patients with “very good”/ “excellent” health status. The Hosmer-Lemeshow goodness-of-fit statistic (p=0.15) indicated that this model was a reasonable fit. Also the final model confirmed good discrimination, since the area under the Receiver Operating Characteristics (ROC) curve was 0.702. The area under the ROC curve that ranges from zero to one presents a measure of the model’s ability to discriminate between those subjects who experience the outcome of interest versus those who do not (69).

A summary of these findings by research question follows:

1. The prevalence of noncompliance following stent placement was 31 %.
  - a. The patients in compliant and noncompliant groups significantly differed by age, gender, health status, smoking status and medication affordability/cost.
  - b. Patients’ general satisfaction was 77.49%, satisfaction with interpersonal manners was 95.94%, satisfaction with communication was 88.19% and satisfaction with discharge instructions was 97.79%.
2. Medication compliance was not associated with patient satisfaction. In multivariate analysis medication compliance was associated with medication affordability/cost, age and health status (“very good”/“excellent” versus “good”).

## **6. Discussion**

This study estimated the prevalence of noncompliance with medications in patients with stent placement in NMMC. Only 69% of the patients were compliant. According to the published

literature, noncompliance rates for the general population generally range from 10% to 40%, and up to 65% for conditions requiring long-term compliance (19; 25; 26; 28). Particularly, according to the results of the study assessing noncompliance in atherothrombotic clinical trials (27; 28), almost 10% among screened post-ischemic stroke patients, discontinued taking their prescribed aspirin. The abovementioned study suggests that there are even greater risks for noncompliance in patients treated with ticlopidine and clopidogrel. In the current study assessing medication noncompliance with aspirin and clopidogrel, the findings are consistent with the published literature. Adherence to medications was also assessed in patients after Coronary Artery Bypass Graft (CABG) surgery in NMMC in 2007. Almost 39% were compliant (e. g., 61% noncompliant) with prescribed medications by MAS scale (67). The observed differences in the medication compliance may be due to the study populations (PCI-patients versus CABG-patients). Patients undergoing CABG surgery do not rely on medications as much as PCI patients, making less emphasized the role of medication compliance in their health outcomes. Before implanting a drug-eluting stent (DES), however, an interventional cardiologist discusses with a PCI-patient the need for and the duration of the antiplatelet therapy to confirm the patient's willingness to comply, also increasing the likelihood of compliance. In addition, medication compliance for the PCI and CABG studies involved different drug categories, with different regimens and potential side-effects that could yield different rates of compliance. Surprisingly, in post acute MI patients (68) only 25% were adherent to physicians' instructions, about 54% were fairly adherent, and about 22% were poorly adherent. The findings imply that for the patients with CHD the rates for medication compliance and adherence to physical activity are inconsistent, suggesting that the patients underestimate the role of physical activity in their health outcomes.

The study also measured patient satisfaction with care, discharge instructions, and the physician-patient relationship in NMMC in patients with stent placement. For this purpose general satisfaction, satisfaction with communication, satisfaction with interpersonal manner and satisfaction with discharge instructions were measured. All these aspects of satisfaction were rated highly, which is not surprising: according to the study performed in the Inpatient Clinic in NMMC in 2003, 96% of patients were satisfied by nursing and 92% by doctor care at Outpatient Clinic (65). According to another study conducted in NMMC, relating lost to follow-up of patients at the Outpatient Clinic, in the group of patients remaining in the follow-up 94.5% were satisfied with services and in the group of patients lost to follow-up 89.7% were satisfied(65).

Overall, satisfaction was quite skewed to better results. Such high satisfaction levels could underestimate the proposed association between medication noncompliance and patient satisfaction. This fact may explain the finding of no statistically significant association between compliance and different aspects of patient satisfaction, which is inconsistent with the published literature. In summary, study patients who were compliant with their prescribed medications differed significantly from noncompliant patients by age, gender, health status, smoking status, and medication affordability/cost. All these findings are supported by the published literature.

An association was found between medication noncompliance and medication affordability/cost. The finding was supported by literature and also by a prior study conducted at NMMC (67).

Older patients were more likely to be compliant, consistent with the literature (25; 30) and with the findings of the study on post acute MI patients (68). Health status was associated to medication compliance as well. Patients with “very good”/”excellent” health status were significantly more likely to be compliant, than patients with “good” health status, but, contrary

to the literature (41; 42), “fair”/“poor” health status patients were not. This null finding might be explained by only a small fraction of the patients (about 8%) that reported “fair” or “poor” health status, thus yielding unstable parameter estimates given the size of the study population.

## **7. Study limitations**

The study population was chosen by simple random sampling, strengthening the internal validity of the findings. Inclusion and exclusion criteria were consistent with previous studies and maximized the generalizability of the findings. Still, the study design and environment imposed several limitations. One study limitation was that time after stent placement was not accounted for, providing different amounts of time (one to two years) over which to recall and to become noncompliant.

Stent replacement was used as an exclusion criterion. This choice could preferentially exclude patients who were noncompliant in the past or were otherwise more likely to be noncompliant in the future. Only 5 such patents were excluded, limiting the effect of any such bias.

By excluding deceased patients, differential mortality among noncompliant cases could underreport the association. Only 7 patients were excluded due to death. While the causes of death were not available; a review of their medical histories did not reveal any consistent deviation from a typical patient profile in terms of health status, disease severity, co-morbidities, etc.

Another limitation is using self-reported information on medication compliance, which could be subject to reporting bias. Patients could overestimate their drug-taking behaviors by answering the desired options for the questions. Likewise, patients’ health status is also a self-reported

measure. While a known and reliable indicator, it can deviate from objective measures of health status. Any such bias would likely result in findings closer to the null.

## **8. Conclusion and recommendations**

Medication compliance following percutaneous coronary intervention (PCI) was 69%. The independent predictors of medication compliance were cost, health status and age. These findings are consistent with previous research. Interestingly, patient satisfaction was not associated with medication compliance. The generally high satisfaction level among all patients at NMMC might explain the null finding. Younger patients with “fair” or “poor” perceived health status and for whom the cost of buying the prescribed medications represents a problem, are more at-risk for noncompliance. NMMC should target these groups with future quality assurance activities that address medication noncompliance and ensuring better health outcomes.

Taking into consideration the mentioned limitations, further study that takes into account time period since stent placement should be conducted. Likewise, further study is needed to assess the impact of medication noncompliance on health outcomes. A qualitative study could provide useful in more fully identifying the main obstacles to medication noncompliance as well as opportunities to increase compliance.

A known obstacle to medication compliance was medication affordability/cost (67). To improve the situation with noncompliance and, thus, further outcomes of treatment, the government, the pharmaceutical industry, and health system advocates should implement efforts to reduce the economic burden on patients. In addition to following treatment guidelines, physicians should

continually reinforce lifestyle advice for secondary prevention of heart attacks (e.g., smoking cessation, controlling high blood pressure).

## Reference List

1. Cardiovascular diseases. World Health Organization Web site.  
<http://www.who.int/mediacentre/factsheets/fs317/en> Accessed December 24, 2008.
2. The top 10 causes of death. Fact sheet No 310. World Health Organization Web site.  
<http://www.who.int/mediacentre/factsheets/fs310/en/> November 2008. Accessed January 18, 2009.
3. Stent. Wikipedia Web Site. <http://en.wikipedia.org/wiki/Stent> Accessed December 22, 2008.
4. Bittle JA. Advances in coronary angioplasty. *N Engl J Med* 1996;335:1290–1302.
5. Serruys PW, Van Hout B, Bonnier H, et al, for the Benestent Study Group: Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). *Lancet* 1998;352:673–681.
6. Lincoff AM, Califf RM, Moliterno DJ, et al, for the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. *N Engl J Med* 1999;341:319–327.
7. Haude M, Höpp HW, Rupprecht HJ, et al, on behalf of the STENT-BY study group: Immediate stent implantation versus conventional techniques for the treatment of abrupt vessel closure or symptomatic dissections after coronary balloon angioplasty. *Am Heart J* 2000; 140:e26.

8. Topol EJ. Coronary-artery stents-gauging, gorging, and gouging. *N Engl J Med* 1998;339:1702–1704.
9. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: evolving issues and current concepts. *J Am Coll Cardiol* 1996;27:494–503.
10. Cutlip DE, Baim DS, Ho KKL, et al. Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials. *Circulation* 2001;103:1967–1971.
11. ten Berg et al. Current Controlled Trials in Cardiovascular Medicine. June 2001;2(3)
12. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Anesth Prog Journal*, 2007;54:161-162.
13. Kevin B. O'Reilly. Physicians can do their part by regularly asking patients whether they are having trouble taking their medicine. *AMNews staff*. Sept. 10, 2007.
14. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization Web site. 2003 <http://www.who.int/medicinedocs/collect/medicinedocs/pdf/s4883e/s4883e.pdf>  
Accessed January 25, 2009.
15. Jones G. Prescribing and taking medicines. *BMJ* 2003;327:819 –820.

16. Morris LS, Schulz RM. Patient compliance-an overview. *J Clin Pharm Ther* 1992;17:283–95.
17. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. *JAMA* 2002;288:2868 –2879.
18. Serebruany VL, Malinin AI, Sane DC, et al. Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. *Eur J Pharmacol.* 2004; 499: 315–324.
19. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? *Am Heart Journal.* 2004;147:293–300.
20. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction: the Physicians' Health Study. *Arch Intern Med.* 1994;154: 2649–2657.
21. Andrew O. Maree, Desmond J. Fitzgerald. Variable Platelet Response to Aspirin and Clopidogrel in Atherotrombotic Disease. *Circulation.* 2007;115:2196-2207.
22. Paul Hjemdahl. Should we monitor platelet function during antiplatelet therapy? *Heart* 2008; 94:685-687.
23. Gurbel PA, Tantry US. Clopidogrel resistance? *Thromb Res* 2007; 120: 311–21.
24. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies – clopidogrel: does one size fit all? *Circulation* 2006; 114: e601–6.

25. S Perreault, L Blais, D Lamarre, et al. Persistence and determinants of statin therapy among middle- aged patients for primary and secondary prevention. *British Journal of Clinical Pharmacology* 2005 May;59(5):564–573.

26. Moreira LB, Fernandes PF, Mota RS, et al. Medication noncompliance in chronic kidney disease. *Journal of Nephrology* 2008 May-Jun;21(3):354-62.

27. Serebruany V. Atorvastatin: Clopidogrel Interactions, Clopidogrel Resistance, and Noncompliance in Atherothrombotic Clinical Trials.

<http://www.medscape.com/viewarticle/466281>

Accessed December 16, 2008.

28. Serebruany V, Malinin A, Sane D, Takserman A, Atar D, Hennekens C, for the AGATE Trial Investigators. The AGgrenox versus Aspirin Treatment Evaluation (AGATE) for platelet inhibition after stroke. *Circulation*. 2003;108(Suppl IV): IV-602.

29. Saw J, Steinhubl SR, Berger PP, et al. Lack of adverse clopidogrel-atorvastatin interactions from secondary analyses of a randomized placebo-controlled clopidogrel trial. *Circulation*. 2003; 108:921-924.

30. Young Sik Kim , Sung Sunwoo , Hye Ree Lee , et al. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. *Pharmacoepidemiology and Drug Safety*. 2002;11 (7):593 – 600.

31. Navaratnasingam Janakan, RdeA Seneviratne. Factors Contributing to Medication Noncompliance of Newly Diagnosed Smear-Positive Pulmonary Tuberculosis Patients in the District of Colombo, Sri Lanka [abstract]. *Asia-Pacific Journal of Public Health* 2008;20:214.
32. Nancy R. Kressin, Fei Wang, Judith Long, et al. Hypertensive Patients' Race, Health Beliefs, Process of Care, and Medication Adherence. *Society of General Internal Medicine* 2007;22:768–774.
33. John A. Spertus, Richard Kettelkamp, Clifton Vance, et al. Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement [abstract]. *Circulation*. 2006;113:2803-2809.
34. Medication Noncompliance After Kidney Transplantation. *Am J Health-Syst Pharm* 2003; 60(3):266-269,
35. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly [abstract]. *Arch Intern Med*. 1990 Apr;150(4):841-5.
36. Moser D.J., Cohen R.A., Clark M.M., et al. Neuropsychological functioning among cardiac rehabilitation patients. *Journal of Cardiopulmonary Rehabilitation*. 1999;19(2):91-97.
37. Krueger, K.P., Berger, B.A., Felkey, B. Medication adherence and persistence: a comprehensive review. *Advances in Therapy*. 2005;22(4):313-356.
38. Slifkin RT. Developing policies responsive to barriers to health care among rural residents: what do we need to know? *J Rural Health* 2002;18(Suppl):233– 41.

39. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance and satisfaction. *Otolaryngol Head Neck Surg.* 2007 Jun;136(6 Suppl):S107-24.
40. E.Thomas, H.Burstin, A.O'Neil, E.Orav, T.Brennan. Patient Noncompliance With Medical Advice After the Emergency Department Visit [abstract]. *Annals of Emergency Medicine*, 27(1):49-55.
41. Robert C. Kaplan, Narendra C. Bhalodkar, Edward J. Brown, Jessica White, David L. Brown. Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications. *Preventive Medicine.* 2004 December;39(6):1249-1255.
42. Thomas H. Wroth, Donald E. Pathman. Primary Medication Adherence in a Rural Population: The Role of the Patient-Physician Relationship and Satisfaction with Care. *JABFM* September–October 2006;19(5).
43. Hargraves JL, Wilson IB, Zaslavsky A et al. Adjusting for patient characteristics when analyzing reports from patients about hospital care. *Med Care.* 2001;39:635-641.
44. Kane RL, Maciejewski M, Finch M. The relationship of patient satisfaction with care and clinical outcomes. *Med Care*, 1997; 35: 714-730.
45. Cleary PD, Edgman-Levitan S, Roberts M et al. Patients evaluate their hospital care: A national survey. *Health Aff.* 1991;10:254-267.
46. Covinsky KE, Rosenthal GE, Chren MM et al. The relation between health status changes and patient satisfaction in older hospitalized patients. *J Gen Intern Med.* 1998;13:223-229.

47. Donabedian A. The quality of care. How can it be assessed? *JAMA* 1988;260:1743-1748.
48. Brown VB, Huba GJ, Melchior LA, et al. Satisfaction with innovative community and university health clinic programs for groups of traditionally underserved individuals with HIV/AIDS: empirical models. *Home Health Care Serv Q*. 2001;19(1-2):77-102.
49. Leila Moret, Jean-Michel Nguyen, et al. Improvement of psychometric properties of a scale measuring inpatient satisfaction with care: a better response rate and a reduction of the ceiling effect. *BMC Health Services Research* 2007;7:197.
50. Cheng S, Yang M, Chiang T. Patient satisfaction with an recommendation of a hospital: effects of interpersonal and technical aspects of hospital care. *Int J Qual Health Care*. 2003;15(4):345-355.
51. Hall JA, Dornan MC. Patient socio-demographic characteristics as predictors of satisfaction with medical care: a meta analysis. *Soc Sci Med*. 1990;30:811-818.
52. Cleary PD, McNeil BJ. Patient satisfaction as an indicator of quality care. *Inquiry*.1988;25:25-36.
53. Larsen DE, Rootman I. Physician role performance and patient satisfaction. *Soc Sci Med*. 1976;10:29-32.
54. James Wiley, Karen Garrett, Yu-Teh Chang, Linda Rudolph, Kathy Dervin, Neil Maizlish. What Do Injured Workers Think of Their Medical Care? A report on the development of a survey. San Francisco, 1998.

55. Donabedian A. An introduction to quality assurance in health care. Oxford : Oxford University Press, 2003.
56. John E. Ware, Ron D. Hays, Allyson Ross Davies. Scoring the Medical Outcomes Study Patient Satisfaction Questionnaire: PSQ-III. MOS Memo, August 19, 1987;No.:866.
57. Lu Ann Aday. Designing Conducting Health Surveys. Second Edition ed. 1996.
58. L.Lix NF. Study Design: Research design with Administrative Data.  
[http://www.umanitoba.ca/centres/mchp/protocol\\_external/methods\\_design.shtml#Oxford](http://www.umanitoba.ca/centres/mchp/protocol_external/methods_design.shtml#Oxford)  
2006. Accessed December 25, 2008.
59. American University of Armenia, Center for Health Services Research and Development Primary Health Care Reform Project. Household Health Survey: Baseline Evaluation. 2006. Submitted by: Emerging Markets Group, Ltd. Submitted to: United States Agency for International Development (USAID).
60. NationalSurvey of People with Diabetes. June 2006; v10.  
[http://www.healthcarecommission.org.uk/\\_db/\\_documents/Questionnaire\\_Diabetes\\_survey\\_2006\\_v10\\_200608042427.pdf](http://www.healthcarecommission.org.uk/_db/_documents/Questionnaire_Diabetes_survey_2006_v10_200608042427.pdf) Accessed January 19, 2009.
61. SF-36 questionnaire. 1992 Medical Outcomes Trust.  
<http://www.drbrantigan.com/patient/SF36tosonly.pdf> Accessed January 21, 2009.
62. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986;24:67-74.

63. S.A. Vik, C.J. Maxwell, D.B. Hogan, et al. Assessing Medication Adherence among Older Persons in Community Settings. *Can J Clin Pharmacol* 2005; 12: e152-e16
64. Marshall GN, Hays RD. The Patient Satisfaction Questionnaire Short-Form (PSQ-18) RAND Corporation. 1994; P-7865.
65. Lusine Abrahamyan, Research on Lost to Follow-up of Patients at the Outpatient Clinic of Nork Marash Medical Center. College of Health Sciences, Yerevan, 2003.
66. What is EpiInfo? <http://www.cdc.gov/epiinfo/> Accessed February 08, 2009
67. Aida Nahapetyan, Relationship Between Patients' Knowledge about Post Operative Risk Factors after Coronary Artery Bypass Surgery (CABG) and Adherence to Medication and Lifestyle Changes in Armenia. College of Health Sciences, Yerevan, 2007
68. Mikhayil Melikov, A Study on Adherence to Physicians' Instructions for Physical Activity among Patients with First-Time Acute Myocardial Infarction. College of Health Sciences, Yerevan, 2009
69. Hosmer D, Lemeshow S. *Applied Logistic regression*, 2<sup>nd</sup> edition, New York, Wiley Series in Probability and Statistics, 2000:340.

## Tables

**Table1. Dependant and Independent Study Variables**

<b>Variable definition</b>	<b>Type</b>	<b>Levels of measurement</b>
<b>Dependant (outcome) variable</b>		
<u>Medication noncompliance</u> Do you ever forget to take your medications?	Binary	Measured as: 0=no 1=yes
<u>Medication noncompliance</u> Are you careless at times about taking your medications?	Binary	0=no 1=yes
<u>Medication noncompliance</u> When you feel better, do you sometimes stop taking your medications?	Binary	0=no 1=yes
<u>Medication noncompliance</u> Sometimes if you feel worse when you take your medications, do you stop taking them?	Binary	0=no 1=yes
<u>Morisky Score</u>	Binary	0=noncompliant (2+) 1=compliant (0-1)
<b>Independent variables</b>		
Satisfaction with care received	Numerical ( <i>Binary*</i> )	Measured as continuous variable: sum of scores of items within each scale
Satisfaction with doctor (interpersonal skills)	Numerical ( <i>Binary*</i> )	Measured as continuous variable: sum of scores of items within each scale
Satisfaction with doctor (communication)	Numerical ( <i>Binary*</i> )	Measured as continuous variable: sum of scores of items within each scale
<u>Satisfaction</u>	Binary	0=unsatisfied (mean score 1.0-3.5) 1=satisfied (mean score 4.0-5.0)
Satisfaction with discharge instructions (Did you know enough about when and how much medication to take?)	Nominal	1. Yes 2. No, I would like to know a little bit more 3. No, I would like to know a lot more 4. I didn't take any medication

<b>Variable definition</b>	<b>Type</b>	<b>Levels of measurement</b>
<u>Satisfaction with discharge instructions</u>	Binary	0=unsatisfied (for #2,3,4 options) 1=satisfied (for #1 option)
<u>Health status</u>	Ordinal	1=excellent, 2=very good, 3=good, 4=fair, 5=poor
<u>Discharge instructions</u> Did you get a clear and understandable explanation about how to take the prescribed medicine?	Nominal	1=yes 2=no 3= don't know/remember
<u>Cardiac rehabilitation referral</u> Thinking about the time, when you received care for cardiac rehabilitation, did you agree when your next appointment would be?	Nominal	1=Rarely or not at all 2=Some of the time 3=Almost always
<u>Medication affordability/Cost</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>Absence of prescribed medication</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>Distance travelling</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>Adverse reactions</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>The medicines do not help (Perceive no benefit)</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>Poor memory</u> What was the reason for not following the prescription?	Binary	1=yes 2=no
<u>Smoking status</u> Have you ever smoked cigarettes?	Binary	1=yes 2=no
<u>Smoking status (Current smoker)</u> Do you currently smoke cigarettes?	Binary	1=yes 2=no
<u>Smoking level</u> How many cigarettes per day do you smoke?	Numerical	Measured as continuous variable: -----# of cigarettes
<u>Smoking Status (Q11+Q12)</u>	Ordinal	1. Never 2. Current 3. Former smoker

<b>Variable definition</b>	<b>Type</b>	<b>Levels of measurement</b>
<u>Diabetes</u> Has a doctor ever told you that you have any of the following health problems or conditions?	Binary	1=yes 2=no
<u>Hypertension</u> Has a doctor ever told you that you have any of the following health problems or conditions?	Binary	1=yes 2=no
<u>Heart attack</u> Has a doctor ever told you that you have any of the following health problems or conditions?	Binary	1=yes 2=no
Age	Numerical	Measured as continuous variable: -----Year
Gender	Binary	1=male 2=female
Nationality	Nominal	1=Armenian,2=Russian 3=Yesidi, 4=Other
Marital status	Nominal	1=married, 2=single, 3=divorced,4=widowed
<u>Education</u> The highest level of education that you have completed:	Ordinal	1=School (less than 10 years), 2=School (10 years), 3=Professional technical education (10-13 years),4=Institute/University Postgraduate
<u>Employment</u> Are you currently employed?	Binary	1=yes 2=no
<u>Employment</u> Which of the following best describes your situation?	Nominal	1=Unemployed, looking for work, 2=Unemployed, not looking for work, 3=Can't work due to (permanent) disability, 4=Can't work due to inability to find/afford child care, 5=Student/ attending school, 6=Homemaker, 7=Retired, 8=Self-employed,9=Farmer, 10=Other

<b>Variable definition</b>	<b>Type</b>	<b>Levels of measurement</b>
<u>Income</u> Last month, the approximate amount of household income spent by all of your household members was:	Ordinal	1=Less than 25,000 drams, 2=From 25,000 - 50,000 drams, 3=From 51,000 - 100,000 drams, 4=From 101,000 - 250,000 drams, 5=Above 250,000drams 6=Don't know

\* Variables were measured as continuous, but later were converted into binary variables (1=satisfied, 0=unsatisfied)

**Table 2. Participant demographic and health characteristics**

<b>Variable name</b>	<b>Result (n, %)</b>	
Age (mean±SD)	57.51	± 9.81
Gender		
Male	238	(87.82)
Female	33	(12.18)
Nationality		
Armenian	268	(98.89)
Russian	3	(1.11)
Education		
School (< 10 years)	16	(5.90)
School (10 years)	60	(22.14)
Prof. technical education (10-13)	50	(18.45)
Institute/university	135	(49.82)
Postgraduate	10	(3.69)
Marital status		
Married	261	(96.31)
Single	3	(1.11)
Divorced	1	(0.37)
Widowed	6	(2.21)
Employment		
Employed	143	(52.77)
Unemployed	128	(47.23)
Unemployed,		
Unemployed, looking for work	9	(6.92)
Unemployed, not looking for work	18	(13.85)
Permanently disabled	14	(10.77)
Homemaker	11	(8.46)
Retired	73	(56.15)
Self-employed	2	(1.54)
Farmer	3	(2.31)
Household income (last month)		
Less than 25,000 drams	22	(8.12)
From 25,000 - 50,000 drams	56	(20.66)
From 51,000 - 100,000 drams	74	(27.31)
From 101,000 - 250,000 drams	62	(22.88)
Above 250,000drams	41	(15.13)
Don't know	16	(5.90)
Health status		
Excellent	17	(6.27)
Very good	85	(31.37)
Good	147	(54.24)
Fair	21	(7.75)
Poor	1	1 (0.37)

Smoking status		
Never	61	(22.51)
Former	127	(46.86)
Current	83	(30.63)
Current smoking level (cigarettes per day)		
	4.94	± 9.38
Diabetes		
Yes	52	(19.19)
No	219	(80.81)
Hypertension		
Yes	135	(49.82)
No	136	(50.18)
Heart attack		
Yes	66	(24.35)
No	205	(75.65)
Discharge instructions		
Yes	268	(98.89)
No	1	(0.37)
Don't know/remember	2	(0.74)
Cardiac rehabilitation referral		
Rarely or not at all	10	(3.69)
Some of the time	49	(18.08)
Almost always	212	(78.23)

**Table 3. Participants' Medication Adherence Scale (MAS) score**

<b>Medication Adherence Scale (MAS) score*</b>	<b>Result (n, %)</b>	<b>Cumulative percent. (%)</b>
0	118 (43.54)	(43.54)
1	69 (25.46)	(69.00)
2	53 (19.56)	(88.56)
3	26 (9.59)	(98.15)
4	5 (1.85)	(100.00)

\*Participants with the MAS score 0 or 1 were defined as “compliant”, and with the score 2 or 3 or 4 as “noncompliant”

**Table 4. Medication Adherence Scale (MAS) Items**

<b>Item</b>	<b>Result (n, %)</b>
Forgot to take medication	104 (38.38)
Careless about taking medication	95 (35.06)
When feeling better, stopped taking medicine	58 (21.40)
When feeling worse, stopped taking medicine	16 (5.90)

**Table 5. Participants' satisfaction with constituent domains**

<b>Variable name</b>	<b>Result (n, %)</b>	
General Satisfaction		
Satisfied	210	(77.49)
Unsatisfied	61	(22.51)
Satisfaction with Interpersonal Manners		
Satisfied	260	(95.94)
Unsatisfied	11	(4.06)
Satisfaction with Communication		
Satisfied	239	(88.19)
Unsatisfied	32	(11.81)
Satisfaction with Discharge Instructions		
Satisfied	265	(97.79)
Unsatisfied	6	(2.21)

**Table 6. Results of Standard 2-tailed t-tests and  $\chi^2$  tests**

<b>Variable name</b>	<b>Compliant (n, %)</b>		<b>Noncompliant (n, %)</b>		<b>p-value</b>
Age (mean $\pm$ SD)	58.94 $\pm$ 9.71		54.32 $\pm$ 9.31		0.000
Gender					0.012
Male	158	(84.49)	80	(95.24)	
Female	29	(15.51)	4	(4.76)	
Nationality					0.243
Armenian	184	(98.39)	84	(100.00)	
Russian	3	(1.61)	0	(0.00)	
Education					0.698
School (< 10 years)	13	(6.95)	3	(3.57)	
School (10 years)	39	(20.85)	21	(25.00)	
Prof. technical education (10-13)	35	(18.72)	15	(17.85)	
Institute/university	92	(49.19)	43	(51.19)	
Postgraduate	8	(4.27)	2	(2.38)	
Marital status					0.096
Married	178	(95.18)	83	(98.81)	
Single	3	(1.60)	0	(0.00)	
Divorced	0	(0.00)	1	(1.19)	
Widowed	6	(3.21)	0	(0.00)	
Employment					0.219
Employed	94	(50.26)	49	(58.33)	
Unemployed	93	(49.74)	35	(41.67)	
Household income					0.284
Less than 25,000 drams	15	(8.04)	7	(8.33)	
From 25,000 - 50,000	37	(19.78)	19	(22.62)	
From 51,000 - 100,000	46	(24.59)	28	(33.33)	
From 101,000 - 250,000	50	(26.74)	12	(14.28)	
above 250,000drams	27	(14.44)	14	(16.67)	
Don't know	12	(6.42)	4	(4.76)	
Health status (categorical)					0.030
Very Good/ Excellent	80	(42.78)	22	(26.19)	
Good	94	(50.27)	53	(63.09)	
Fair/Poor	13	(6.95)	9	(10.71)	
Smoking status					0.045
Never	50	(26.74)	11	(13.09)	
Former	83	(44.38)	44	(52.38)	
Current	54	(28.87)	29	(34.52)	
Current smoking level (mean $\pm$ SD) (cigarettes per day)	4.29 $\pm$ 8.58		6.40 $\pm$ 10.88		0.043
Diabetes					0.769
Yes	35	(18.72)	17	(20.24)	
No	152	(81.28)	67	(79.76)	

<b>Variable name</b>	<b>Compliant (n, %)</b>		<b>Noncompliant (n, %)</b>		<b>p-value</b>
Hypertension					0.455
Yes	96	(51.33)	39	(46.43)	
No	91	(48.66)	45	(53.57)	
Heart attack					0.437
Yes	43	(22.99)	23	(27.4)	
No	144	(77.01)	61	(72.6)	
Discharge instructions					0.085
Yes	186	(99.46)	82	(97.62)	
No	1	(0.54)	0	(0.00)	
Don't know/remember	0	(0.00)	2	(2.38)	
Cardiac rehabilitation referral					0.324
Rarely or not at all					
Some of the time	6	(3.21)	4	(4.76)	
Almost always	30	(16.04)	19	(22.62)	
	151	(80.75)	61	(72.62)	
Medication affordability/Cost					0.009
Yes					
No	28	(14.97)	24	(28.57)	
	159	(85.03)	60	(71.43)	
Absence of prescribed medication					0.444
Yes					
No	8	(4.28)	2	(2.38)	
	179	(95.72)	82	(97.62)	
Distance travelling					0.177
Yes		4 (2.14)	0	(0.00)	
No	183	(97.86)	84	(100.00)	
Poor memory					
Yes	0	(0.00)	0	(0.00)	
No	187	(100.00)	84	(100.00)	
Medications do not help					0.179
Yes	1	(0.53)	2	(2.38)	
No	186	(99.46)	82	(97.62)	
Adverse effects					0.560
Yes	1	(0.53)	1	(1.19)	
No	186	(99.46)	83	(98.81)	
General Satisfaction					0.977
Satisfied	145	(77.54)	65	(77.38)	
Unsatisfied	42	(22.46)	19	(22.62)	
Satisfaction with Interpersonal Manners					0.348
Satisfied	178	(95.18)	82	(97.62)	
Unsatisfied	9	(4.82)	2	(2.38)	
Satisfaction with Communication					0.210
Satisfied	168	(89.84)	71	(84.52)	
Unsatisfied	19	(10.16)	13	(15.48)	

<b>Variable name</b>	<b>Compliant (n, %)</b>		<b>Noncompliant (n, %)</b>		<b>p-value</b>
Satisfaction with Discharge Instructions					0.900
Satisfied	183	(97.86)	82	(97.62)	
Unsatisfied	4	(2.14)	2	(2.38)	

**Table 7. Results of Bivariate Logistic Regression Analyses (Crude Odds Ratios)**


<b>Variable name</b>	<b>Odds Ratio</b>	<b>95% CI</b>	<b>p-value</b>
Age	1.05	1.02 - 1.08	0.000
Gender	3.67	1.25 - 10.81	0.018
Health status (categorical)			
Very Good /Excellent	2.05	1.15 - 3.66	0.015
Good	1.00		
Fair/Poor	0.81	0.33 - 2.03	0.660
Smoking status			
Never	1.00		
Former	0.41	0.20 - 0.88	0.021
Current	0.40	0.18 - 0.90	0.028
Current smoking level (cigarettes per day)	0.97	0.95 - 1.00	0.090
Diabetes	1.10	0.57 - 2.10	0.769
Hypertension	0.82	0.49 - 1.37	0.455
Heart attack	1.26	0.70 - 2.27	0.437
Discharge instructions	0.28	0.05 - 1.61	0.154
Cardiac rehabilitation referral	1.42	0.88 - 2.29	0.154
Medication affordability/Cost	2.27	1.22 - 4.22	0.010
Absence of prescribed medication	0.54	0.11 - 2.63	0.450
Medications do not help	4.53	0.41 - 50.74	0.220
Adverse effects	2.24	0.14 - 36.26	0.570
General Satisfaction	1.01	0.54 - 1.87	0.977
Satisfaction with Interpersonal Manners	0.48	0.10 - 2.28	0.358
Satisfaction with Communication	1.62	0.76 - 3.45	0.213
Satisfaction with Discharge Instructions	1.11	0.20 - 6.21	0.900

**Table 8. Results of Multiple Logistic Regression Analyses: Adjusted Effect of Independent Variables on Medication Compliance**

<b>Variable name</b>	<b>Odds Ratio</b>	<b>95 % CI</b>	<b>p-value</b>
<b>Cost</b>			
Yes	1.00	referent	
No	2.57	1.33-4.97	0.005
<b>Health status</b>			
Very Good /Excellent	2.17	1.18-4.01	0.013
Good	1.00	referent	
Fair/Poor	0.87	0.34-2.23	0.783
<b>Age</b>	1.06	1.03-1.09	0.000

## Figures

Figure 1. Distribution of Scores of Domains of Satisfaction





## Appendix 2. Questionnaire (English & Armenian) Questionnaire

ID \_\_\_\_\_

Date of the interview \_\_\_\_\_ (Day/Month/Year)

Start time of the interview \_\_\_\_\_ (Hour/Minute)

End time of the interview \_\_\_\_\_ (Hour/Minute)

**The answer should be marked by circling the number corresponding to the option or filling the blanks.**

### **A. Demographic**

**Please, indicate your:**

*(Circle one)*

1. Age: \_\_\_\_\_

2. Gender:

1. Male
2. Female

### **B. Discharge information**

**After you undergo stent placement,**

*(Circle one)*

3. Did your doctor prescribed you medicines?

1. Yes
2. No *(Go to Q.5)*
88. Don't know/don't remember *(Go to Q.5)*

4. Did you get a clear and understandable explanation about how to take the prescribed medicine (time of day and dosage)?

1. Yes
2. No
88. Don't know/remember

5. Thinking about the time, when you received care for cardiac rehabilitation, did you agree when your next appointment would be?

1. Rarely or not at all
2. Some of the time
3. Almost always

6. Please list the **PRESCRIPTION** medications you have taken.

1. Aspirin
2. Plavix
3. Other (specify)

### C. Patient Satisfaction

7. Did you know enough about when and how much medication to take?

*(Circle one)*

1. Yes
2. No, I would like to know a little bit more
3. No, I would like to know a lot more
4. I didn't take any medication

8. How strongly do you **AGREE** or **DISAGREE** with each of the following statements?

*(Circle one on each line)*

	Strongly agree	Agree	Uncertain	Disagree	Strongly disagree
<b>A. General Satisfaction</b>					
<b>1. The medical care I have been receiving is just about perfect</b>	1	2	3	4	5
<b>2. I am dissatisfied with some things about the medical care I receive</b>	1	2	3	4	5

<b>B. Interpersonal Manner</b>					
<b>3. Doctors act too businesslike and impersonal toward me</b>	1	2	3	4	5
<b>4. My doctor treat me in a very friendly and courteous manner</b>	1	2	3	4	5
<b>C. Communication</b>					
<b>5. Doctors are good about explaining the reason for medical tests</b>	1	2	3	4	5
<b>6. Doctors sometimes ignore what I tell them</b>	1	2	3	4	5

**D. Health status/ Health Behavior**

*(Circle one)*

9. In general, would you say your health is:

1. Excellent
2. Very good
3. Good
4. Fair
5. Poor

10. Compared to one year ago how would you rate your health in general now?

1. Much better now than one year ago
2. Somewhat better now than one year ago

3. About the same as one year ago
4. Somewhat worse now than one year ago
5. Much worse now than one year ago

11. Have you ever smoked cigarettes?

1. Yes
2. No (*Go to Q.14*)

12. Do you currently smoke cigarettes?

1. Yes
2. No (*Go to Q.14*)

13. How many cigarettes per day do you smoke? \_\_\_\_\_ cigarettes

14. Has a doctor ever told you that you have any of the following health problems or conditions?

*(Circle all that apply)*

1. Diabetes
2. High blood pressure
3. Heart attack
4. Other (*describe*) \_\_\_\_\_

## **E. Medication Compliance**

**Thinking about the medications PRESCRIBED to you by your doctor(s), please answer the following questions:**

*(Circle one)*

15. Do you ever forget to take your medications?

1. Yes
2. No

16. Are you careless at times about taking your medications?

1. Yes
2. No

17. When you feel better, do you sometimes stop taking your medications?

1. Yes
2. No

18. Sometimes if you feel worse when you take your medications, do you stop taking them?

1. Yes
2. No

19. What was the reason for not following the prescription?

*(Circle all that apply)*

1. Was unable to buy medicine(s) because of cost
2. Was unable to get medicine(s) because of absence of concomitant medications
3. Was unable to get medicine(s) because of distance travelling
4. Side effects/fear of side effects
5. Forgot to take medicine(s)
6. The medicines do not help
7. Other (*describe*) \_\_\_\_\_

## **F. Socio-Demographic**

**Please, indicate your:**

*(Circle one)*

20. Nationality:

1. Armenian
2. Russian
3. Yesidi
4. Other (*describe*) \_\_\_\_\_

21. Marital status

1. Married
2. Single
3. Divorced
4. Widowed

22. The highest level of education that you have completed:

1. School (less than 10 years)
2. School (10 years)
3. Professional technical education (10-13 years)
4. Institute/University
5. Postgraduate

23. Are you currently employed?

1. Yes (*Go to Q25*)
2. No

24. Which of the following best describes your situation?

1. Unemployed, looking for work
2. Unemployed, not looking for work
3. Can't work due to (permanent) disability
4. Can't work due to inability to find/afford child care
5. Student/attending school
6. Homemaker
7. Retired
8. Self-employed
9. Farmer
10. Other \_\_\_\_\_

25. Last month, the approximate amount of household income spent by all of your household members was:

1. Less than 25,000 drams
2. From 25,000 - 50,000 drams
3. From 51,000 - 100,000 drams
4. From 101,000 - 250,000 drams
5. Above 250,000drams
88. Don't know

## Հարցաթերթիկ

Տարբերակման համարը \_\_\_\_\_

Հարցման օրը \_\_\_\_\_ օր/ամիս/տարի)

Հարցման սկիզբը \_\_\_\_\_ (ժամ/րոպե)

Հարցման ավարտը \_\_\_\_\_ (ժամ/րոպե)

Պատասխանը պետք է նշվի՝ շրջանակի մեջ վերցնելով տարբերակին համապատասխանող թիվը կամ լրացնելով տողերը

### Ա. Դեմոգրաֆիկ տվյալներ

Նշեք Ձեր՝

*(նշեք մեկ պատասխան)*

1. Տարիքը. \_\_\_\_\_

2. Սեռը \_\_\_\_\_

1. արական
2. իգական

### Բ. Դուրս գրման տեղեկություններ

Ստենտավորումից հետո՝

*(նշեք մեկ պատասխան)*

3. Ձեր բժիշկը Ձեզ դեղորայք նշանակե՞լ է

1. այո
2. ոչ *(անցնել 5-րդ հարցին)*
3. չգիտեմ/ չեմ հիշում *(անցնել 5-րդ հարցին)*

4. Դուք ստացե՞լ եք պարզ և հասկանալի բացատրություն Ձեր դեղորայքն ընդունելու մասին (ընդունման ժամերի և դեղաչափերի վերաբերյալ)

1. այո
2. ոչ
3. չգիտեմ/ չեմ հիշում

5. Հիշելով այն ժամանակաշրջանի մասին, երբ բուժում էիք ստանում սրտային հիվանդությունների վերականգնման համար, Գուք բժշկի հետ համաձայնեցնում էիք Ձեր հաջորդ հանդիպումը

1. հազվադեպ կամ երբեք
2. երբեմն
3. համարյա միշտ

6. Նշեք բժշկի կողմից նշանակված դեղորայքները, որ Գուք ընդունել եք

\_\_\_\_\_ Aspirin \_\_\_\_\_  
 \_\_\_\_\_ (Plavix) \_\_\_\_\_  
 \_\_\_\_\_ Այլ (նշեք) \_\_\_\_\_

**Գ. Հիվանդի բավարարվածություն**

7. Գուք բավարար չափո՞վ էիք տեղեկացվածայն մասին, թե երբ և ինչ քանակությամբ դեղորայք ընդունել

*(նշեք մեկ պատասխան)*

1. այո
2. ոչ, կցանկանայի իմանալ մի քիչ ավելին
3. ոչ, կցանկանայի իմանալ շատ ավելին
4. ես որևէ դեղորայք չեմ ընդունել

8. Ինչքանո՞վ եք համաձայն, կամ համաձայն չեք հետևյալ պնդումներից յուրաքանչյուրի հետ.

*(նշեք մեկ պատասխան՝ յուրաքանչյուր տողում)*

	Լիովին համաձայն եմ	Համաձայն եմ	Դժվարանում եմ պատասխանել	Համաձայն չեմ	Բոլորովին համաձայն չեմ
<b>Ա.Ընդհանուր Բավարարվածություն</b>					
Իմ ստացած բուժօգնությունը կարելի է համարել կատարյալ	1	2	3	4	5
Ես դժգոհ եմ որոշ բաներից կապված իմ ստացած բուժօգնության հետ	1	2	3	4	5

<b>Բ.Շփման Վարվելակերպ</b>					
Բժիշկների գործելակերպը իմ նկատմամբ շատ գործնական և անտարբեր է	1	2	3	4	5
Իմ բժիշկն ինձ վերաբերվում է շատ բարյացակամ և քաղաքավարի	1	2	3	4	5
<b>Գ.Հաղորդակցություն</b>					
Բժիշկները լավ են բացատրում բժշկական տեստերի անցկացման անհրաժեշտությունը	1	2	3	4	5
Բժիշկները երբեմն անտեսում են իմ ասածները	1	2	3	4	5

**Գ. Առողջական վիճակ և առողջ վարքագիծ**

*(նշեք մեկ պատասխան)*

9. Ինչպե՞ս կբնութագրեք Ձեր առողջական վիճակն ընդհանրապես

1. գերազանց
2. լավ
3. բավարար
4. վատ
5. շատ վատ

10. Համեմատած անցյալ տարվա հետ, ինչպե՞ս կգնահատեք Ձեր առողջական վիճակը հիմա

1. Հիմա շատ ավելի լավ, քան մեկ տարի առաջ
2. Հիմա որոշ չափով ավելի լավ, քան մեկ տարի առաջ
3. Համարյա միևնույնը, ինչ մեկ տարի առաջ
4. Հիմա որոշ չափով ավելի վատ, քան մեկ տարի առաջ
5. Հիմա շատ ավելի վատ, քան մեկ տարի առաջ

11. Գուք երբևէ սիգարետ ծխե՞լ եք

1. այո
2. ոչ *(անցնել 14-րդ հարցին)*

12. Գուք ներկայումս ծխու՞մ եք

1. այո
2. ըչ *(անցնել 14-րդ հարցին)*

13. Օրական միջին հաշվով քանի՞ սիգարետ եք ծխում \_\_\_\_\_ սիգարետ

14. Բժիշկը երբևիցե ասե՞լ է ձեզ, որ Գուք ունեք հետևյալ առողջական խնդիրներից կամ վիճակներից որևէ մեկը

*(նշեք բոլոր համապատասխան պատասխանները)*

1. Գիաբետ
2. Արյան քարձր ճնշում
3. Սրտային նոպա
4. Այլ (նշեք) \_\_\_\_\_

### **Ե. Նշանակված դեղորայքի համապատասխան ընդունում**

**Մտածելով Ձեր՝ բժշկի կողմից նշանակված դեղորայքի մասին, պատասխանեք խնդրեմ հետևյալ հարցերին.**

*(նշեք մեկ պատասխան)*

15. Գուք երբևիցե մոռանու՞մ եք ընդունել Ձեր դեղորայքը

1. այո
2. ոչ

16. Գուք անուշադի՞ր եք Ձեր դեղորայքն ընդունելու ժամանակի մասին

1. այո
2. ոչ

17. Երբ Ձեզ լավ եք զգում, երբևիցե դադարեցնու՞մ եք Ձեր դեղորայքի ընդունում

1. այո
2. ոչ

18. Երբեմն երբ Ձեզ վատ եք զգում դեղորայք ընդունելիս, Գուք երբևիցե դադարեցնու՞մ եք դեղորայքի ընդունումը

1. այո
2. ոչ

19. Ի՞նչն է հանդիսացել նշանակմանը չհետևելու պատճառը

*(նշեք բոլոր համապատասխան պատասխանները)*

1. Անկարող էի գնել դեղորայք(ներ) գնի պատճառով
2. Անկարող էի գնել դեղորայք(ներ) համապատասխան դեղորայքի բացակայության պատճառով
3. Անկարող էի գնել դեղորայք(ներ) հեռավորություն ճանապարհորդելու պատճառով
4. Կողմնակի էֆեկտներ/Վախ կողմնակի էֆեկտներից
5. Մոռացել եմ դեղորայք(ներ) ընդունել
6. Դեղորայքները չեն օգնում
7. Այլ (նշեք)\_\_\_\_\_

## Ձ. Սոցիալ- դեմոգրաֆիկ տվյալներ

Նշեք Ձեր՝

*(նշեք մեկ պատասխան)*

20. Ազգությունը

1. հայ
2. ռուս
3. եզդի
4. այլ (նշեք) \_\_\_\_\_

21. Ամուսնական կարգավիճակը

1. ամուսնացած
2. ամուրի
3. ամուսնալուծված
4. այրի

22. Ձեր ստացած կրթության ամենաբարձր մակարդակը

1. թերի միջնակարգ (10 տարուց պակաս)
2. միջնակարգ (10 տարի)
3. միջնակարգ մասնագիտական (10-13 տարի)
4. համալսարան, ԲՈՒՀ
5. հետդիպլոմային

23. Ներկայումս դուք աշխատու՞մ եք

1. այո
2. ըչ *(անցնել 25-րդ հարցին)*

24. Ո՞րն է լավագույնս բնութագրում Ձեր կարգավիճակը

1. գործազուրկ եմ, աշխատանք եմ փնտրում
2. գործազուրկ եմ, աշխատանք չեմ փնտրում
3. չեմ կարող աշխատել (մշտական) հաշմանդամության պատճառով
4. չեմ կարող աշխատել մանկան խնամքը ապահովելու անկարողության պատճառով
5. ուսանող եմ/դպրոց եմ հաճախում
6. տնային տնտես(ուհի) եմ
7. թոշակառու եմ
8. ձեռներեց եմ
9. ֆերմեր եմ
10. այլ (նշեք) \_\_\_\_\_

25. Անցյալ ամիս Ձեր ընտանիքի բոլոր անդամների կողմից ունեցած միջին ամսեկան եկամուտը կազմել է՝

1. ոչ ավելի, քան 25,000 դրամ
2. 25,000-50,000 դրամ
3. 51,000-100,000 դրամ
4. 101,000-250,000 դրամ
5. ավելի քան 250,000 դրամ
6. չգիտեմ

## Appendix 3. Consent Form (English & Armenian)

### Oral Consent Form

**Title of Research Project:** Patient Satisfaction and Medication Noncompliance following Percutaneous Coronary Intervention in Armenia

---

#### **Explanation of Research Project:**

Hello, My Name is Seda Aghabekyan. I am a second year student of Public Health Department at American University of Armenia. As a part of my Master Project I am conducting a research study to assess patient satisfaction at Nork-Marash Medical Center following stent placement. You are asked to participate in the study because you are one of 375 randomly selected patients, who had a procedure involving a stent at NMMC.

If you do not mind, I am going to ask you some questions related to your health, satisfaction and medication compliance. Questions will not be of personal or of a sensitive nature and will not cause any harm to you. Your participation is highly valued by NMMC. The interview will take less than 15 minutes.

There are no any risks for you to participate in this study. Your participation or refusal is not connected with your further treatment at the center. The only inconvenience will be your time spent on the interview but you will not be compensated for your time. You will not receive any benefits from your participation but your answers will contribute to the further improvement of the quality of health services of NMMC.

Your confidentiality will be assured. Only I, as a researcher, will have access to personal identifiers with names and phone numbers of the study participants. And these identifiers will be destroyed after the study is finished. Information will only be reported in an aggregate/summarized form and it will not be possible to identify your responses in the report.

Participation in this survey is voluntary and you can withdraw from the study at any time you want.

If you would like to get more information you can contact Varduhi Petrosyan, Associate Dean, College of Health Sciences: (010) 51 25 64, e-mail: [vpetrosi@aua.am](mailto:vpetrosi@aua.am) or the student investigator Seda Aghabekyan, (091) 221998, e-mail: [seda\\_ghabekyan@edu.aua.am](mailto:seda_ghabekyan@edu.aua.am). If you want to talk to anyone about the study as you feel that you have been treated unfairly or have been hurt, you can contact Yelena Amirkhanyan, the chair of Institutional Review Board: (010) 512592, e-mail: [yamirkh@aua.am](mailto:yamirkh@aua.am).

## Հարցման մասնակցության համաձայնագիր

**Հետազոտության անվանում**՝ Հիվանդների բավարարվածությունն ու նշանակված դեղորայքի համապատասխան ընդունումը ներմաշկային կորոնար միջամտությունից (ստենտավորումից) հետո Հայաստանում:

### Հետազոտության բացատրություն

Բարև Ձեզ, իմ անունը Սեդա Աղաբեկյան է: Ես Հայաստանի Ամերիկյան Համալսարանի Հանրային առողջապահության ֆակուլտետի ավարտական կուրսի ուսանող եմ: Որպես իմ դիպլոմային աշխատանքի մի մաս, ես հետազոտություն եմ կատարում, գնահատելու հիվանդների բավարարվածությունը ստենտավորումից հետոՆորք-Մարաշ բժշկական կենտրոնում (ՆՄԲԿ): Ձեզ խնդրում եմ մասնակցել այս հարցմանը, քանի որ դուք ներառվել եք այն 375 պատահականորեն ընտրված մարդկանց շարքում, որոնք ստենտավորվել են ՆՄԲԿ-ում:

Եթե Դուք դեմ չեք, ես Ձեզ մի քանի հարց կտամ՝ կապված Ձեր առողջության, բավարարվածության և նշանակված դեղորայքի համապատասխան ընդունման հետ: Հարցերը անձնական կամ նուրբ զգայական բնույթի չեն և Ձեզ ոչ մի վնաս չեն պատճառի: Ձեր մասնակցությունը բարձր կգնահատվի ՆՄԲԿ-ի կողմից: Հարցումը կտևի 15 րոպեից քիչ:

Այս հետազոտությանը մասնակցելով Դուք որևէ ռիսկի չեք դիմում: Ձեր մասնակցությունը կամ հրաժարումը ոչ մի կերպ չի անդրադառնա կենտրոնում Ձեր հետագա բուժման հետ: Ձեզ պատճառած միակ անհարմարությունը կապված է այն ժամանակի հետ, որը կտրամադրեք հարցազրույցին, բայց Դուք դրա համար չեք փոխհատուցվի: Ձեր մասնակցությունից Դուք որևէ շահույթ չեք ունենա, բայց Ձեր պատասխանը կնպաստի ՆՄԲԿ բուժառայությունների որակի հետագա բարելավմանը:

Ձեր գաղտնիությունը կապահովվի: Միայն ինձ, որպես հետազոտող, հասանելի կլինի հետազոտության մասնակիցների ինքնությունը հաստատող տվյալները՝ անունները և հեռախոսահամարները: Այս տվյալները կոչնչացվեն անմիջապես հետազոտության ավարտից հետո: Ձեր կողմից տրամադրված անձնական տեղեկատվությունը կզեկուցվի միայն ամփոփ ձևով, և Ձեր պատասխանները զեկույցում տարբերակել հնարավոր չի լինի:

Մասնակցությունը ըստ ցանկության է, և Դուք կարող եք դադարեցնել հարցազրույցը ցանկացած պահի:

Եթե Դուք կցանկանաք ստանալ ավելի մանրամասն տեղեկություններ, ապա կարող եք դիմել Վարդուհի Պետրոսյանին՝ Առողջապահական գիտությունների քոլեջի

փոխդեկանին, (010) 51 25 92, էլ-փոստ՝ [vpetrosi@aua.am](mailto:vpetrosi@aua.am), կամ ինձ՝ Սեդա Աղաբեկյանիս, (091) 221998, էլ-փոստ՝ [seda\\_ghabekyan@edu.aua.am](mailto:seda_ghabekyan@edu.aua.am): Եթե Ռուք ցանկանաք խոսել հետազոտության մասին, քանի որ գտնում եք, որ Ձեզ ոչ ազնիվ կամ վատ են վերաբերվել ապա կարող եք զանգահարել Ելենա Ամիրխանյանին՝ էթիկայի հանձնաժողովի նախագահին, (010) 51 25 92, էլ-փոստ՝ [yamirkh@aua.am](mailto:yamirkh@aua.am):